Short-term efficacy and safety of lasmiditan, a novel 5-HT(1F) receptor agonist, for the acute treatment of migraine: a systematic review and meta-analysis

BACKGROUND: Migraine has been recognized as one of common diseases in the world whose current treatment options are not ideal. Lasmiditan, an oral 5-hydroxytryptamine (HT)(1F) receptor agonist, appears more promising for the acute treatment of migraine because of considerably better effect profiles...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Min, Xing, Haiyan, Li, Chen, Wang, Xianfeng, Deng, Dongmei, Li, Juan, Zhang, Pan, Chen, Jianhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275414/
https://www.ncbi.nlm.nih.gov/pubmed/32503415
http://dx.doi.org/10.1186/s10194-020-01138-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275414/
https://www.ncbi.nlm.nih.gov/pubmed/32503415
http://dx.doi.org/10.1186/s10194-020-01138-x

Ejemplares similares